MedTrace Logo

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

NCT01615627 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-03-03

No results posted yet for this study

Summary

The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.

Conditions

Interventions

DRUG

HypotonicTreprostinil Solution

Hypotonic Treprostinil Solution

DRUG

Eutonic Treprostinil Solution

Eutonic Treprostinil Solution

Sponsors & Collaborators

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • David Langleben, MD · Jewish General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-01
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01615627 on ClinicalTrials.gov